
Polish firm Perlan Technologies and 2curex have signed an agreement entailing the launch of the Danish firm's cancer test, Inditreat, on the Polish market, 2curex announces in a press release.
Under terms of the deal, Perlan is tasked with the domestic marketing of Inditreat which tests a patient's tumor and predicts tumor responses to different drugs, providing information to physicians about individual patient treatments.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app